|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
November 25, 2005Optical coherence tomography: measuring in-vivo axonal survival and neuroprotection in MS and optic neuritis
"A new tool is beginning to enter imaging techniques used by neurologists studying MS - Optical Coherence Tomography. This is a method of non-invasively measuring the thickness of the retinal nerve fiber down to micron level thickness. This can allow measurement of axonal degeneration so that we can measure the effectiveness of neuroprotective agents. The tool itself is not new, but its use in MS is.MORE: Entrez PubMed
|